Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PN400 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | PN400 + ASA |
| 2 | PLACEBO_COMPARATOR | Placebo + ASA |
| Name | Type | Description |
|---|---|---|
| PN400 | DRUG | naproxen 500 mg/esomeprazole 20 mg oral tablet |
| ASA | DRUG | Asprin 81 mg enteric coated tablet |
| Placebo | DRUG | - |
Inclusion Criteria: * Stable without clinically significant disease Exclusion Criteria: * Use of NSAID within 2 weeks * Type 1 or 2 DM * GI disorder
PN400 is an investigational small molecule developed by AstraZeneca PLC for platelet inhibition in hematology. It is a Phase 1 clinical candidate, meaning it has not been approved by the FDA and remains in early-stage development. The program has completed one Phase 1 trial with 40 participants.
PN400 is being developed for platelet inhibition. Its only completed clinical trial enrolled healthy volunteers aged 50 years and older to assess inhibition of serum thromboxane B2 levels. The drug is investigational and has not been approved for any indication.
PN400 is developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the single completed Phase 1 trial of PN400 conducted in the United States.
PN400 is in Phase 1 development. One Phase 1 trial has been completed, and there are no active trials. The drug is investigational and has not received FDA approval. The completed study was randomized, double-blind, and placebo-controlled, enrolling 40 healthy volunteers.
PN400 has been studied in one completed Phase 1 trial, NCT01094483, titled "A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin." It enrolled 40 healthy volunteers in the United States and was randomized, double-blind, and placebo-controlled.